<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360226</url>
  </required_header>
  <id_info>
    <org_study_id>REG-RES1801</org_study_id>
    <nct_id>NCT04360226</nct_id>
  </id_info>
  <brief_title>Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations</brief_title>
  <official_title>Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respiratory Effectiveness Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Respiratory Effectiveness Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, mulitcentre, observational, prospective study into Peak Inspiratory
      Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak
      Inspiratory Flow (PIF) and inadequate inhaler choice and assess the baseline characteristics
      of these groups. B) Assess the clinical role of PIF and inhaler choice in predicting COPD
      exacerbations and symptom burden. C) Assess the variability and correlation of PIF with other
      lung function measurements and CAT score in stable COPD. It is a 12 month study comprising
      one baseline assessment and 2 follow-up visits at 6 and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of suboptimal PIF and inadequate inhaler choice.</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine the prevalence of suboptimal PIF and inadequate inhaler choice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first exacerbation associated with different levels of PIF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PIF and symptom burden</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
    <description>PIF measurements will be correlated with COPD Assessment Test (CAT) Scores. CAT scores range from 0-40 depending on the severity of a persons symptoms; higher scores denote a more severe impact of COPD on a patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Annual mortality rate associated with different PIF levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability and correlation of PIF</measure>
    <time_frame>Baseline, 6 and 12 months</time_frame>
    <description>Variability of PIF over time and the correlation between PIF and other lung function measures (including FEV1, FVC, Inspiratory capacity), CAT scores, T2 markers (nasal polyps and dermatitis) and where available blood biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Annual rate of exacerbations associated with different PIF levels</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients, who are clinically stable (4 exacerbations in previous 4 weeks) and have
        been taking inhaled medications for at least 6 months, but have no other chronic
        respiratory conditions, other than asthma or bronchiectasis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Spirometry-defined COPD (i.e. post-bronchodilator FEV1/FVC&lt;0.7)

          2. Age â‰¥40 years

          3. Smokers or ex-smokers of at least 10 pack-years

          4. Clinically stable COPD (no exacerbations in the last 4 weeks)

          5. Capable of performing serial lung function tests

          6. Prescribed inhaled medication for at least 6 months

        Exclusion Criteria:

          1. Occurrence of an COPD exacerbation during the previous 4 weeks

          2. Have any concomitant chronic respiratory condition other than asthma or bronchiectasis
             (e.g. cystic fibrosis, lung fibrosis, tuberculosis)

          3. Are unable to understand the instructions of the study or to fill the questionnaires

          4. Are unwilling to sign the informed consent

          5. Are participating in a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Usmani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart and Lung Institute, Imperial College London &amp; Royal Brompton Hosp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omar Usmani, MD</last_name>
    <phone>+44 (0)20 7351 8051</phone>
    <email>o.usmani@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Lucas, PhD</last_name>
    <email>sarah@REGresearchnetwork.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Miravitlles, MD</last_name>
      <email>marcm@separ.es</email>
    </contact>
    <investigator>
      <last_name>Marc Miravitlles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

